NOTCH1 and acute lymphoblastic leukemia: It was suggested that more than 50% T-ALLs have activating mutations that involve the extracellular heterodimerization domain and/or the C-terminal PEST domain of Notch1, thus advocating the need for targeted therapies against Notch signaling T-ALL (Weng et al., 2004).